期刊
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
卷 286, 期 3, 页码 C465-C474出版社
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajpcell.00397.2003
关键词
high-throughput screening; drug development; pharmacology; fluorescence; cystic fibrosis transmembrane conductance regulator
资金
- NEI NIH HHS [EY-13574] Funding Source: Medline
- NHLBI NIH HHS [HL-59198, HL-73856] Funding Source: Medline
- NIBIB NIH HHS [EB-00415] Funding Source: Medline
- NIDDK NIH HHS [DK-35124] Funding Source: Medline
Drug discovery and development is generally done in the commercial rather than the academic realm. Drug discovery involves target discovery and validation, lead identification by high-throughput screening, and lead optimization by medicinal chemistry. Follow-up preclinical evaluation includes analysis in animal models of compound efficacy and pharmacology (ADME: administration, distribution, metabolism, elimination) and studies of toxicology, specificity, and drug interactions. Notwithstanding the high-cost, labor-intensive, and non-hypothesis-driven aspects of drug discovery, the academic setting has a unique and expanding niche in this important area of investigation. For example, academic drug discovery can focus on targets of limited commercial value, such as third-world and rare diseases, and on the development of research reagents such as high-affinity inhibitors for pharmacological gene knockout in animal models (chemical genetics). This review describes the practical aspects of the preclinical drug discovery process for academic investigators. The discovery of small molecule inhibitors and activators of the cystic fibrosis transmembrane conductance regulator is presented as an example of an academic drug discovery program that has yielded new compounds for physiology research and clinical development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据